A type of diabetes mellitus that is characterized by severe INSULIN RESISTANCE and LIPODYSTROPHY. The latter may be generalized, partial, acquired, or congenital (LIPODYSTROPHY, CONGENITAL GENERALIZED).
A collection of heterogenous conditions resulting from defective LIPID METABOLISM and characterized by ADIPOSE TISSUE atrophy. Often there is redistribution of body fat resulting in peripheral fat wasting and central adiposity. They include generalized, localized, congenital, and acquired lipodystrophy.
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
Defective metabolism leading to fat maldistribution in patients infected with HIV. The etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors.
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
Conditions or pathological processes associated with the disease of diabetes mellitus. Due to the impaired control of BLOOD GLUCOSE level in diabetic patients, pathological processes develop in numerous tissues and organs including the EYE, the KIDNEY, the BLOOD VESSELS, and the NERVE TISSUE.
A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).
A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage.
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
Specialized connective tissue composed of fat cells (ADIPOCYTES). It is the site of stored FATS, usually in the form of TRIGLYCERIDES. In mammals, there are two types of adipose tissue, the WHITE FAT and the BROWN FAT. Their relative distributions vary in different species with most adipose tissue being white.
Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY.
Glucose in blood.
Diabetes mellitus induced by PREGNANCY but resolved at the end of pregnancy. It does not include previously diagnosed diabetics who become pregnant (PREGNANCY IN DIABETICS). Gestational diabetes usually develops in late pregnancy when insulin antagonistic hormones peaks leading to INSULIN RESISTANCE; GLUCOSE INTOLERANCE; and HYPERGLYCEMIA.
Substances which lower blood glucose levels.
Minor hemoglobin components of human erythrocytes designated A1a, A1b, and A1c. Hemoglobin A1c is most important since its sugar moiety is glucose covalently bound to the terminal amino acid of the beta chain. Since normal glycohemoglobin concentrations exclude marked blood glucose fluctuations over the preceding three to four weeks, the concentration of glycosylated hemoglobin A is a more reliable index of the blood sugar average over a long period of time.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Abnormally high BLOOD GLUCOSE level.
A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg).
VASCULAR DISEASES that are associated with DIABETES MELLITUS.
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)

Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. (1/24)

In lipoatrophic diabetes, a lack of fat is associated with insulin resistance and hyperglycemia. This is in striking contrast to the usual association of diabetes with obesity. To understand the underlying mechanisms, we transplanted adipose tissue into A-ZIP/F-1 mice, which have a severe form of lipoatrophic diabetes. Transplantation of wild-type fat reversed the hyperglycemia, dramatically lowered insulin levels, and improved muscle insulin sensitivity, demonstrating that the diabetes in A-ZIP/F-1 mice is caused by the lack of adipose tissue. All aspects of the A-ZIP/F-1 phenotype including hyperphagia, hepatic steatosis, and somatomegaly were either partially or completely reversed. However, the improvement in triglyceride and FFA levels was modest. Donor fat taken from parametrial and subcutaneous sites was equally effective in reversing the phenotype. The beneficial effects of transplantation were dose dependent and required near-physiological amounts of transplanted fat. Transplantation of genetically modified fat into A-ZIP/F-1 mice is a new and powerful technique for studying adipose physiology and the metabolic and endocrine communication between adipose tissue and the rest of the body.  (+info)

Cardiac involvement in total generalized lipodystrophy (Berardinelli- Seip syndrome). (2/24)

Total generalized lipodystrophy (Berardinelli - Seip Syndrome) is a rare hereditary disease characterized by insulin-resistant diabetes mellitus and a small quantity of adipose tissue and is of unknown origin. Common cardiovascular alterations related to this syndrome are cardiac hypertrophy and arterial hypertension. This article reports a case of Berardinelli - Seip syndrome and reviews the literature with special emphasis on the cardiovascular manifestations of this syndrome.  (+info)

Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. (3/24)

There is uncertainty about the site(s) of action of the antidiabetic thiazolidinediones (TZDs). These drugs are agonist ligands of the transcription factor PPAR gamma, which is abundant in adipose tissue but is normally present at very low levels in liver and muscle. We have studied the effects of TZDs in A-ZIP/F-1 mice, which lack white adipose tissue. The A-ZIP/F-1 phenotype strikingly resembles that of humans with severe lipoatrophic diabetes, including the lack of fat, marked insulin resistance and hyperglycemia, hyperlipidemia, and fatty liver. Rosiglitazone or troglitazone treatment did not reduce glucose or insulin levels, suggesting that white adipose tissue is required for the antidiabetic effects of TZDs. However, TZD treatment was effective in lowering circulating triglycerides and increasing whole body fatty acid oxidation in the A-ZIP/F-1 mice, indicating that this effect occurs via targets other than white adipose tissue. A-ZIP/F-1 mice have markedly increased liver PPAR gamma mRNA levels, which may be a general property of fatty livers. Rosiglitazone treatment increased the triglyceride content of the steatotic livers of A-ZIP/F-1 and ob/ob mice, but not the "lean" livers of fat-transplanted A-ZIP/F-1 mice. In light of this evidence that rosiglitazone acts differently in steatotic livers, the effects of rosiglitazone, particularly on hepatic triglyceride levels, should be examined in humans with hepatic steatosis.  (+info)

Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. (4/24)

Lipoatrophic diabetes is caused by a deficiency of adipose tissue and is characterized by severe insulin resistance, hypoleptinemia, and hyperphagia. The A-ZIP/F-1 mouse (A-ZIPTg/+) is a model of severe lipoatrophic diabetes and is insulin resistant, hypoleptinemic, hyperphagic, and shows severe hepatic steatosis. We have also produced transgenic "skinny" mice that have hepatic overexpression of leptin (LepTg/+) and no adipocyte triglyceride stores, and are hypophagic and show increased insulin sensitivity. To explore the pathophysiological and therapeutic roles of leptin in lipoatrophic diabetes, we crossed LepTg/+ and A-ZIPTg/+ mice, producing doubly transgenic mice (LepTg/+:A-ZIPTg/+) virtually lacking adipose tissue but having greatly elevated leptin levels. The LepTg/+:A-ZIPTg/+ mice were hypophagic and showed improved hepatic steatosis. Glucose and insulin tolerance tests revealed increased insulin sensitivity, comparable to LepTg/+ mice. These effects were stable over at least 6 months of age. Pair-feeding the A-ZIPTg/+ mice to the amount of food consumed by LepTg/+:A-ZIPTg/+ mice did not improve their insulin resistance, diabetes, or hepatic steatosis, demonstrating that the beneficial effects of leptin were not due to the decreased food intake. Continuous leptin administration that elevates plasma leptin concentrations to those of LepTg/+:A-ZIPTg/+ mice also effectively improved hepatic steatosis and the disorder of glucose and lipid metabolism in A-ZIP/F-1 mice. These data demonstrate that leptin can improve the insulin resistance and diabetes of a mouse model of severe lipoatrophic diabetes, suggesting that leptin may be therapeutically useful in the long-term treatment of lipoatrophic diabetes.  (+info)

WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. (5/24)

WY14,643 is a specific peroxisome proliferator-activated receptor alpha (PPARalpha) agonist with strong hypolipidemic effects. Here we have examined the effect of WY14,643 in the A-ZIP/F-1 mouse, a model of severe lipoatrophic diabetes. With 1 week of treatment, all doses of WY14,643 that were tested normalized serum triglyceride and fatty acid levels. Glucose and insulin levels also improved but only with high doses and longer treatment duration. WY14,643 reduced liver and muscle triglyceride content and increased levels of mRNA encoding fatty acid oxidation enzymes. In liver, the elevated lipogenic mRNA profile (including PPARgamma) in A-ZIP/F-1 mice remained unchanged. These results suggest that WY14,643 acts by increasing beta-oxidation rather by than decreasing lipogenesis or lipid uptake. Hyperinsulinemic euglycemic clamp studies indicated that WY14,643 treatment improved liver more than muscle insulin sensitivity and that hepatic mRNA levels of gluconeogenic enzymes were reduced. Combination treatment with both WY14,643 and a PPARgamma ligand, rosiglitazone, did not lower glucose levels more effectively than did treatment with WY14,643 alone. These data support the hypothesis that reducing intracellular triglycerides in non-adipose tissues improves insulin sensitivity and suggest that further investigation of the role of PPARalpha agonists in the treatment of lipoatrophic diabetes is warranted.  (+info)

Adrenalectomy improves diabetes in A-ZIP/F-1 lipoatrophic mice by increasing both liver and muscle insulin sensitivity. (6/24)

The virtually fatless A-ZIP/F-1 mouse is profoundly insulin resistant, diabetic, and a good model for humans with severe generalized lipoatrophy. Like a number of other mouse models of diabetes, the A-ZIP/F-1 mouse has elevated serum corticosterone levels. Leptin infusion lowers the corticosterone levels, suggesting that leptin deficiency contributes to the hypercorticosteronemic state. To test the hypothesis that the increased glucocorticoids contribute to the diabetes and insulin resistance, we examined the effect of adrenalectomy on A-ZIP/F-1 mice. Adrenalectomy significantly decreased the blood glucose, serum insulin, and glycated hemoglobin levels. Hyperinsulinemic-euglycemic clamps were performed to characterize the changes in whole-body and tissue insulin sensitivity. The adrenalectomized A-ZIP/F-1 mice displayed a marked improvement in insulin-induced suppression of endogenous glucose production, indicating increased hepatic insulin sensitivity. Adrenalectomy also increased muscle glucose uptake and glycogen synthesis. These results suggest that the chronically increased serum corticosterone levels contribute to the diabetes of the A-ZIP/F-1 mice and that removal of the glucocorticoid excess improves the insulin sensitivity in both muscle and liver.  (+info)

Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy. (7/24)

Severe adipose tissue deficiency (lipoatrophy) causes insulin-resistant diabetes, elevated serum triglyceride and fatty acid levels, and massive triglyceride deposition in the liver. In lipoatrophic A-ZIP/F-1 mice, transplantation of normal adipose tissue greatly improved these parameters, whereas 1 week of leptin infusion had more modest effects. In contrast, leptin infusion was strikingly more effective in the aP2-n sterol response element binding protein 1 lipoatrophic mouse. Here we show that a longer duration of leptin infusion further improves the metabolic status of the A-ZIP/F-1 mice and that genetic background does not make a major contribution to the effect of leptin on glucose and insulin levels. Adipose transplantation using leptin-deficient ob/ob fat had no effect on the phenotype of the A-ZIP/F-1 mice. Moreover, the presence of ob/ob adipose tissue did not enhance the effects of leptin infusion. Serum adiponectin levels were 2% of control levels in the A-ZIP/F-1 mouse and increased only twofold with adipose transplantation and not at all after leptin infusion, suggesting that adiponectin deficiency is not a major contributor to the diabetic phenotype. Taken together, these results suggest that sequestration of triglycerides into fat may not be enough to restore a nondiabetic phenotype and that leptin deficiency plays a major role in causing the metabolic complications of lipoatrophy.  (+info)

Diabetes-induced, progressive endometrial involution characterization of periluminal epithelial lipoatrophy. (8/24)

The present studies detail the cytopathological alterations in uterine epithelial, basal lamina, and stromal endometrial subregions, and associated endocrine parameters that occur during the progressive exacerbation of the diabetes syndrome in this species of mouse. These alterations result in a cellular lipoatrophic condition that compromises uterine tissue integrity and promotes reproductive involution. Uterine tissue samples were obtained from litter-matched control (+/?) and diabetic (db/db) C57BL/KsJ mice at four designated stages of the progressive expression of the diabetes mutation. In db/db mice between the ages of 4 and 12 weeks, the uterine epithelial cellular architecture exhibited progressive deterioration, characterized by cytoplasmic lipid imbibition (accumulation), organelle disintegration, apical membrane ciliary regression, and peristromal lamina separation from basal membrane surfaces, as compared with control indexes. The cytoplasmic volume occupied by lipid inclusions dominated the epithelial cells in diabetic mice, presenting dense basal pole lipid vacuoles, with perinuclear-intracytoplasmic migration of the inclusions promoting an apical cytoplasmic lipid condensation of increasing volume 8-12 weeks after mutation expression. These cytoplasmic lipid accumulations occurred under altered metabolic and endocrine conditions characterized by hyperglycemic, hyperinsulinemic, hypertriglyceridemic, and enhanced noradrenergic indexes, which were exacerbated between 4- and 12-week stages. These structural changes were accompanied by enhanced adrenergic counterregulatory metabolic responses as well as elevated lipoprotein and triacylglycerol lipase activities. These data indicate that diabetes-associated uterine involution is characterized by a progressive cellular and peristromal lipoatrophy of epithelial cell cytology and metabolic parameters, promoting stromal separation and ultimate endometrial involution.  (+info)

Diabetes Mellitus, Lipoatrophic is not a recognized medical term or official classification for diabetes. However, Lipodystrophy is a condition that can occur in some people with diabetes, particularly those being treated with insulin. Lipodystrophy refers to the loss of fat tissue, which can cause changes in the way the body responds to insulin and lead to difficulties controlling blood sugar levels. There are different types of lipodystrophy, including localized lipoatrophy (small areas of fat loss) and generalized lipodystrophy (widespread fat loss).

In people with Diabetes Mellitus, Lipodystrophy can lead to an increased need for insulin, as well as other metabolic complications. It is important for individuals with diabetes who notice changes in their body's response to insulin or unusual fat distribution to consult with their healthcare provider for further evaluation and management.

Lipodystrophy is a medical condition characterized by abnormal distribution or absence of fat (adipose tissue) in the body. It can lead to metabolic complications such as insulin resistance, diabetes mellitus, high levels of fats in the blood (dyslipidemia), and liver disease. There are different types of lipodystrophy, including congenital generalized lipodystrophy, acquired generalized lipodystrophy, and partial lipodystrophy, which can affect different parts of the body and have varying symptoms and causes.

Diabetes Mellitus, Type 2 is a metabolic disorder characterized by high blood glucose (or sugar) levels resulting from the body's inability to produce sufficient amounts of insulin or effectively use the insulin it produces. This form of diabetes usually develops gradually over several years and is often associated with older age, obesity, physical inactivity, family history of diabetes, and certain ethnicities.

In Type 2 diabetes, the body's cells become resistant to insulin, meaning they don't respond properly to the hormone. As a result, the pancreas produces more insulin to help glucose enter the cells. Over time, the pancreas can't keep up with the increased demand, leading to high blood glucose levels and diabetes.

Type 2 diabetes is managed through lifestyle modifications such as weight loss, regular exercise, and a healthy diet. Medications, including insulin therapy, may also be necessary to control blood glucose levels and prevent long-term complications associated with the disease, such as heart disease, nerve damage, kidney damage, and vision loss.

Diabetes Mellitus is a chronic metabolic disorder characterized by elevated levels of glucose in the blood (hyperglycemia) due to absolute or relative deficiency in insulin secretion and/or insulin action. There are two main types: Type 1 diabetes, which results from the autoimmune destruction of pancreatic beta cells leading to insulin deficiency, and Type 2 diabetes, which is associated with insulin resistance and relative insulin deficiency.

Type 1 diabetes typically presents in childhood or young adulthood, while Type 2 diabetes tends to occur later in life, often in association with obesity and physical inactivity. Both types of diabetes can lead to long-term complications such as damage to the eyes, kidneys, nerves, and cardiovascular system if left untreated or not well controlled.

The diagnosis of diabetes is usually made based on fasting plasma glucose levels, oral glucose tolerance tests, or hemoglobin A1c (HbA1c) levels. Treatment typically involves lifestyle modifications such as diet and exercise, along with medications to lower blood glucose levels and manage associated conditions.

HIV-Associated Lipodystrophy Syndrome is a term used to describe a range of body shape changes and metabolic abnormalities that can occur in some individuals receiving long-term combination antiretroviral therapy (cART) for HIV infection. The syndrome is characterized by the abnormal distribution of fat, including:

1. Lipoatrophy: Loss of subcutaneous fat from the face, limbs, and buttocks, leading to a gaunt appearance.
2. Lipohypertrophy: Accumulation of fat in the abdomen, breasts, and dorsocervical region (buffalo hump), resulting in an altered body shape.
3. Metabolic abnormalities: Insulin resistance, hyperlipidemia, and lactic acidosis, which can increase the risk of developing cardiovascular disease and diabetes mellitus.

The exact pathogenesis of HIV-Associated Lipodystrophy Syndrome is not fully understood, but it is believed to be related to a combination of factors, including the direct effects of HIV infection on adipose tissue, mitochondrial toxicity caused by certain antiretroviral medications, and chronic inflammation. The syndrome can have significant psychological and social consequences for affected individuals, and management typically involves a multidisciplinary approach that includes switching to alternative antiretroviral regimens, addressing metabolic abnormalities, and providing cosmetic interventions as needed.

Diabetes Mellitus, Type 1 is a chronic autoimmune disease characterized by the destruction of insulin-producing beta cells in the pancreas, leading to an absolute deficiency of insulin. This results in an inability to regulate blood glucose levels, causing hyperglycemia (high blood sugar). Type 1 diabetes typically presents in childhood or early adulthood, although it can develop at any age. It is usually managed with regular insulin injections or the use of an insulin pump, along with monitoring of blood glucose levels and adjustments to diet and physical activity. Uncontrolled type 1 diabetes can lead to serious complications such as kidney damage, nerve damage, blindness, and cardiovascular disease.

Diabetes complications refer to a range of health issues that can develop as a result of poorly managed diabetes over time. These complications can affect various parts of the body and can be classified into two main categories: macrovascular and microvascular.

Macrovascular complications include:

* Cardiovascular disease (CVD): People with diabetes are at an increased risk of developing CVD, including coronary artery disease, peripheral artery disease, and stroke.
* Peripheral arterial disease (PAD): This condition affects the blood vessels that supply oxygen and nutrients to the limbs, particularly the legs. PAD can cause pain, numbness, or weakness in the legs and may increase the risk of amputation.

Microvascular complications include:

* Diabetic neuropathy: This is a type of nerve damage that can occur due to prolonged high blood sugar levels. It commonly affects the feet and legs, causing symptoms such as numbness, tingling, or pain.
* Diabetic retinopathy: This condition affects the blood vessels in the eye and can cause vision loss or blindness if left untreated.
* Diabetic nephropathy: This is a type of kidney damage that can occur due to diabetes. It can lead to kidney failure if not managed properly.

Other complications of diabetes include:

* Increased risk of infections, particularly skin and urinary tract infections.
* Slow healing of wounds, which can increase the risk of infection and amputation.
* Gum disease and other oral health problems.
* Hearing impairment.
* Sexual dysfunction.

Preventing or managing diabetes complications involves maintaining good blood sugar control, regular monitoring of blood glucose levels, following a healthy lifestyle, and receiving routine medical care.

Insulin is a hormone produced by the beta cells of the pancreatic islets, primarily in response to elevated levels of glucose in the circulating blood. It plays a crucial role in regulating blood glucose levels and facilitating the uptake and utilization of glucose by peripheral tissues, such as muscle and adipose tissue, for energy production and storage. Insulin also inhibits glucose production in the liver and promotes the storage of excess glucose as glycogen or triglycerides.

Deficiency in insulin secretion or action leads to impaired glucose regulation and can result in conditions such as diabetes mellitus, characterized by chronic hyperglycemia and associated complications. Exogenous insulin is used as a replacement therapy in individuals with diabetes to help manage their blood glucose levels and prevent long-term complications.

Leptin is a hormone primarily produced and released by adipocytes, which are the fat cells in our body. It plays a crucial role in regulating energy balance and appetite by sending signals to the brain when the body has had enough food. This helps control body weight by suppressing hunger and increasing energy expenditure. Leptin also influences various metabolic processes, including glucose homeostasis, neuroendocrine function, and immune response. Defects in leptin signaling can lead to obesity and other metabolic disorders.

Insulin resistance is a condition in which the body's cells become less responsive to insulin, a hormone produced by the pancreas that regulates blood sugar levels. In response to this decreased sensitivity, the pancreas produces more insulin to help glucose enter the cells. However, over time, the pancreas may not be able to keep up with the increased demand for insulin, leading to high levels of glucose in the blood and potentially resulting in type 2 diabetes, prediabetes, or other health issues such as metabolic syndrome, cardiovascular disease, and non-alcoholic fatty liver disease. Insulin resistance is often associated with obesity, physical inactivity, and genetic factors.

Adipose tissue, also known as fatty tissue, is a type of connective tissue that is composed mainly of adipocytes (fat cells). It is found throughout the body, but is particularly abundant in the abdominal cavity, beneath the skin, and around organs such as the heart and kidneys.

Adipose tissue serves several important functions in the body. One of its primary roles is to store energy in the form of fat, which can be mobilized and used as an energy source during periods of fasting or exercise. Adipose tissue also provides insulation and cushioning for the body, and produces hormones that help regulate metabolism, appetite, and reproductive function.

There are two main types of adipose tissue: white adipose tissue (WAT) and brown adipose tissue (BAT). WAT is the more common form and is responsible for storing energy as fat. BAT, on the other hand, contains a higher number of mitochondria and is involved in heat production and energy expenditure.

Excessive accumulation of adipose tissue can lead to obesity, which is associated with an increased risk of various health problems such as diabetes, heart disease, and certain types of cancer.

I couldn't find a medical definition specifically for "Diabetes Mellitus, Experimental." However, I can provide you with information about experimental diabetes research and its relevance to understanding the disease.

Experimental diabetes models are used in biomedical research to study the pathophysiology of diabetes mellitus and to test potential therapies or treatments. These models can be broadly categorized into two types: chemically-induced and genetically modified.

1. Chemically-induced diabetes models: These involve administering chemicals, such as alloxan or streptozotocin, to animals (commonly mice or rats) to destroy their pancreatic β-cells, which produce insulin. This results in hyperglycemia and symptoms similar to those seen in type 1 diabetes in humans.
2. Genetically modified diabetes models: These involve altering the genes of animals (commonly mice) to create a diabetes phenotype. Examples include non-obese diabetic (NOD) mice, which develop an autoimmune form of diabetes similar to human type 1 diabetes, and various strains of obese mice with insulin resistance, such as ob/ob or db/db mice, which model aspects of type 2 diabetes.

These experimental models help researchers better understand the mechanisms behind diabetes development and progression, identify new therapeutic targets, and test potential treatments before moving on to human clinical trials. However, it's essential to recognize that these models may not fully replicate all aspects of human diabetes, so findings from animal studies should be interpreted with caution.

Blood glucose, also known as blood sugar, is the concentration of glucose in the blood. Glucose is a simple sugar that serves as the main source of energy for the body's cells. It is carried to each cell through the bloodstream and is absorbed into the cells with the help of insulin, a hormone produced by the pancreas.

The normal range for blood glucose levels in humans is typically between 70 and 130 milligrams per deciliter (mg/dL) when fasting, and less than 180 mg/dL after meals. Levels that are consistently higher than this may indicate diabetes or other metabolic disorders.

Blood glucose levels can be measured through a variety of methods, including fingerstick blood tests, continuous glucose monitoring systems, and laboratory tests. Regular monitoring of blood glucose levels is important for people with diabetes to help manage their condition and prevent complications.

Gestational diabetes is a type of diabetes that occurs during pregnancy. It is characterized by an increase in blood sugar levels that begins or is first recognized during pregnancy. The condition usually develops around the 24th week of gestation and is caused by the body's inability to produce enough insulin to meet the increased demands of pregnancy.

Gestational diabetes typically resolves after delivery, but women who have had gestational diabetes are at an increased risk of developing type 2 diabetes later in life. It is important for women with gestational diabetes to manage their blood sugar levels during pregnancy to reduce the risk of complications for both the mother and the baby.

Management of gestational diabetes may include lifestyle modifications such as dietary changes and exercise, as well as monitoring blood sugar levels and potentially using insulin or other medications to control blood sugar levels. Regular prenatal care is essential for women with gestational diabetes to ensure that their blood sugar levels are properly managed and to monitor the growth and development of the fetus.

Hypoglycemic agents are a class of medications that are used to lower blood glucose levels in the treatment of diabetes mellitus. These medications work by increasing insulin sensitivity, stimulating insulin release from the pancreas, or inhibiting glucose production in the liver. Examples of hypoglycemic agents include sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists. It's important to note that the term "hypoglycemic" refers to a condition of abnormally low blood glucose levels, but in this context, the term is used to describe agents that are used to treat high blood glucose levels (hyperglycemia) associated with diabetes.

Glycosylated Hemoglobin A, also known as Hemoglobin A1c or HbA1c, is a form of hemoglobin that is bound to glucose. It is formed in a non-enzymatic glycation reaction with glucose in the blood. The amount of this hemoglobin present in the blood is proportional to the average plasma glucose concentration over the previous 8-12 weeks, making it a useful indicator for monitoring long-term blood glucose control in people with diabetes mellitus.

In other words, HbA1c reflects the integrated effects of glucose regulation over time and is an important clinical marker for assessing glycemic control and risk of diabetic complications. The normal range for HbA1c in individuals without diabetes is typically less than 5.7%, while a value greater than 6.5% is indicative of diabetes.

Medical Definition:

"Risk factors" are any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury. They can be divided into modifiable and non-modifiable risk factors. Modifiable risk factors are those that can be changed through lifestyle choices or medical treatment, while non-modifiable risk factors are inherent traits such as age, gender, or genetic predisposition. Examples of modifiable risk factors include smoking, alcohol consumption, physical inactivity, and unhealthy diet, while non-modifiable risk factors include age, sex, and family history. It is important to note that having a risk factor does not guarantee that a person will develop the disease, but rather indicates an increased susceptibility.

Hyperglycemia is a medical term that refers to an abnormally high level of glucose (sugar) in the blood. Fasting hyperglycemia is defined as a fasting blood glucose level greater than or equal to 126 mg/dL (milligrams per deciliter) on two separate occasions. Alternatively, a random blood glucose level greater than or equal to 200 mg/dL in combination with symptoms of hyperglycemia (such as increased thirst, frequent urination, blurred vision, and fatigue) can also indicate hyperglycemia.

Hyperglycemia is often associated with diabetes mellitus, a chronic metabolic disorder characterized by high blood glucose levels due to insulin resistance or insufficient insulin production. However, hyperglycemia can also occur in other conditions such as stress, surgery, infection, certain medications, and hormonal imbalances.

Prolonged or untreated hyperglycemia can lead to serious complications such as diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), and long-term damage to various organs such as the eyes, kidneys, nerves, and blood vessels. Therefore, it is essential to monitor blood glucose levels regularly and maintain them within normal ranges through proper diet, exercise, medication, and lifestyle modifications.

A Glucose Tolerance Test (GTT) is a medical test used to diagnose prediabetes, type 2 diabetes, and gestational diabetes. It measures how well your body is able to process glucose, which is a type of sugar.

During the test, you will be asked to fast (not eat or drink anything except water) for at least eight hours before the test. Then, a healthcare professional will take a blood sample to measure your fasting blood sugar level. After that, you will be given a sugary drink containing a specific amount of glucose. Your blood sugar levels will be measured again after two hours and sometimes also after one hour.

The results of the test will indicate how well your body is able to process the glucose and whether you have normal, impaired, or diabetic glucose tolerance. If your blood sugar levels are higher than normal but not high enough to be diagnosed with diabetes, you may have prediabetes, which means that you are at increased risk of developing type 2 diabetes in the future.

It is important to note that a Glucose Tolerance Test should be performed under the supervision of a healthcare professional, as high blood sugar levels can be dangerous if not properly managed.

Diabetic angiopathies refer to a group of vascular complications that occur due to diabetes mellitus. Prolonged exposure to high blood sugar levels can damage the blood vessels, leading to various types of angiopathies such as:

1. Diabetic retinopathy: This is a condition where the small blood vessels in the retina get damaged due to diabetes, leading to vision loss or blindness if left untreated.
2. Diabetic nephropathy: In this condition, the kidneys' glomeruli (the filtering units) become damaged due to diabetes, leading to protein leakage and eventually kidney failure if not managed properly.
3. Diabetic neuropathy: This is a type of nerve damage caused by diabetes that can affect various parts of the body, including the legs, feet, and hands, causing numbness, tingling, or pain.
4. Diabetic cardiomyopathy: This is a condition where the heart muscle becomes damaged due to diabetes, leading to heart failure.
5. Diabetic peripheral arterial disease (PAD): In this condition, the blood vessels that supply the legs and feet become narrowed or blocked due to diabetes, leading to pain, cramping, or even gangrene in severe cases.

Overall, diabetic angiopathies are serious complications of diabetes that can significantly impact a person's quality of life and overall health. Therefore, it is crucial for individuals with diabetes to manage their blood sugar levels effectively and undergo regular check-ups to detect any early signs of these complications.

Diabetic nephropathy is a kidney disease that occurs as a complication of diabetes. It is also known as diabetic kidney disease (DKD). This condition affects the ability of the kidneys to filter waste and excess fluids from the blood, leading to their accumulation in the body.

Diabetic nephropathy is caused by damage to the small blood vessels in the kidneys, which can occur over time due to high levels of glucose in the blood. This damage can lead to scarring and thickening of the kidney's filtering membranes, reducing their ability to function properly.

Symptoms of diabetic nephropathy may include proteinuria (the presence of protein in the urine), edema (swelling in the legs, ankles, or feet due to fluid retention), and hypertension (high blood pressure). Over time, if left untreated, diabetic nephropathy can progress to end-stage kidney disease, which requires dialysis or a kidney transplant.

Preventing or delaying the onset of diabetic nephropathy involves maintaining good control of blood sugar levels, keeping blood pressure under control, and making lifestyle changes such as quitting smoking, eating a healthy diet, and getting regular exercise. Regular monitoring of kidney function through urine tests and blood tests is also important for early detection and treatment of this condition.

Diabetic neuropathies refer to a group of nerve disorders that are caused by diabetes. High blood sugar levels can injure nerves throughout the body, but diabetic neuropathies most commonly affect the nerves in the legs and feet.

There are four main types of diabetic neuropathies:

1. Peripheral neuropathy: This is the most common type of diabetic neuropathy. It affects the nerves in the legs and feet, causing symptoms such as numbness, tingling, burning, or shooting pain.
2. Autonomic neuropathy: This type of neuropathy affects the autonomic nerves, which control involuntary functions such as heart rate, blood pressure, digestion, and bladder function. Symptoms may include dizziness, fainting, digestive problems, sexual dysfunction, and difficulty regulating body temperature.
3. Proximal neuropathy: Also known as diabetic amyotrophy, this type of neuropathy affects the nerves in the hips, thighs, or buttocks, causing weakness, pain, and difficulty walking.
4. Focal neuropathy: This type of neuropathy affects a single nerve or group of nerves, causing symptoms such as weakness, numbness, or pain in the affected area. Focal neuropathies can occur anywhere in the body, but they are most common in the head, torso, and legs.

The risk of developing diabetic neuropathies increases with the duration of diabetes and poor blood sugar control. Other factors that may contribute to the development of diabetic neuropathies include genetics, age, smoking, and alcohol consumption.

... is a type of diabetes mellitus presenting with severe lipodystrophy in addition to the traditional signs ... "Lipoatrophic diabetes mellitus treated by continuous subcutaneous insulin infusion". Diabetes Metab. 24 (6): 544-6. PMID ... Morse A, Whitaker M (2000). "Successful pregnancy in a woman with lipoatrophic diabetes mellitus. A case report". J Reprod Med ... "Lipoatrophic diabetes in an elderly woman: clinical course and serum adipocytokine concentrations". Endocr J. 51 (3): 279-86. ...
... diabetes mellitus, lipoatrophic MeSH C19.344.078.265 - adrenal cortex neoplasms MeSH C19.344.078.265.500 - adrenocortical ... diabetes insipidus, neurogenic MeSH C19.700.159.875 - wolfram syndrome MeSH C19.700.355.179 - acromegaly MeSH C19.700.355.528 ...
... diabetes mellitus, type 2 MeSH C18.452.394.750.149.500 - diabetes mellitus, lipoatrophic MeSH C18.452.394.750.448 - diabetes, ... diabetes mellitus MeSH C18.452.394.750.074 - diabetes mellitus, experimental MeSH C18.452.394.750.124 - diabetes mellitus, type ...
... diabetes mellitus, lipoatrophic MeSH C17.800.849.391.400 - HIV-associated lipodystrophy MeSH C17.800.849.495 - necrobiosis ...
It is associated with endocrine dysfunction, especially insulin resistance and hyperinsulinaemia, as seen in diabetes mellitus ... lipoatrophic diabetes, pineal hyperplasia syndrome, pituitary basophilism, ovarian hyperthecosis, stromal luteoma, ovarian ... as seen in diabetes mellitus. Factors involved in the development of acanthosis nigricans include: Increased circulating ... such as diabetes mellitus and metabolic syndrome excess circulating androgens, particularly Cushing's disease, acromegaly, ...
AREDYLD stands for acral renal ectodermal dysplasia lipoatrophic diabetes. AREDLYD is categorized as a rare disease, meaning it ... diabetes mellitus, and amastia: a second case of the AREDYLD syndrome". Am J Med Genet. 44 (3): 374-7. doi:10.1002/ajmg. ... lipoatrophic diabetes, and other manifestations". Am J Med Genet. 16 (1): 29-33. doi:10.1002/ajmg.1320160106. PMID 6638067. ...
The term lipoatrophic diabetes refers to diabetes mellitus in association with lipoatrophy. Lipodystrophy encompasses ... Lipoatrophic diabetes mellitus treated by continuous subcutaneous insulin infusion. Diabetes Metab. 1998 Dec. 24(6):544-6. [ ... Molecular scanning of beta-3-adrenergic receptor gene in total congenital lipoatrophic diabetes mellitus. J Clin Endocrinol ... Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence ...
Lipoatrophic diabetes is a type of diabetes mellitus presenting with severe lipodystrophy in addition to the traditional signs ... "Lipoatrophic diabetes mellitus treated by continuous subcutaneous insulin infusion". Diabetes Metab. 24 (6): 544-6. PMID ... Morse A, Whitaker M (2000). "Successful pregnancy in a woman with lipoatrophic diabetes mellitus. A case report". J Reprod Med ... "Lipoatrophic diabetes in an elderly woman: clinical course and serum adipocytokine concentrations". Endocr J. 51 (3): 279-86. ...
Experimental Diabetes Mellitus; Type 1 Diabetes Mellitus; Wolfram Syndrome; Type 2 Diabetes Mellitus; Lipoatrophic Diabetes ... Experimental Diabetes Mellitus; Type 1 Diabetes Mellitus; Wolfram Syndrome; Type 2 Diabetes Mellitus; Lipoatrophic Diabetes ... Experimental Diabetes Mellitus; Type 1 Diabetes Mellitus; Wolfram Syndrome; Type 2 Diabetes Mellitus; Lipoatrophic Diabetes ... "Type 2 diabetes" (also known as "type 2 diabetes mellitus" or "diabetes mellitus, type 2", and formerly called "diabetes ...
Type 2 Diabetes mellitus (T2DM). *Monogenic diabetes: Neonatal diabetes, MODY-maturity onset diabetes of the young, ... mitochondrial diabetes, and lipoatrophic diabetes[10]. *Diabetes secondary to other pancreatic diseases, endocrinopathies, ... Type 1 diabetes (also called juvenile-onset diabetes mellitus, DM1, T1DM, and insulin-dependent diabetes mellitus) is ... Synonyms and keywords: Pediatric Diabetes Mellitus (DM) Overview. Diabetes mellitus (DM) is the metabolic homeostasis disorder ...
... lipoatrophic diabetes mellitus, Werner syndrome, and phenylketonuria.[43] The pathophysiology is believed to be related to ... and diabetes mellitus. Patients with lipohypertrophy typically have an enlarged dorsocervical fat pad, circumferential ...
DIABETES MELLITUS - General Characteristics, Pancreas, Classification, Etiopathogenesis, Pathological Changes, Clinical ... Lipoatrophic diabetes. • Other. C. Diseases of the exocrine pancreas. • Pancreatitis, Trauma, Pancreatectomy ... ETIOLOGICAL CLASSIFICATION OF DIABETES MELLITUS 1. Type 1 diabetes (cell destruction, usually leading to absolute insulin ... Type-1 diabetes mellitus has been classified into type-1A in which cell-mediated autoimmune attack on the beta cells is more ...
Acanthosis nigricans among women with gestational diabetes mellitus and risk of adverse pregnancy outcomes. Diabetes Care. 2008 ... The type B syndrome generally occurs in women who have uncontrolled diabetes mellitus, ovarian hyperandrogenism, or an ... the Cherokee Diabetes Study. Diabetes Care. 2002 Jun. 25(6):1009-14. [QxMD MEDLINE Link]. ... the American Diabetes Association established acanthosis nigricans as a formal risk factor for the development of diabetes in ...
It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against sodium/glucose ... It is used to treat type 2 diabetes mellitus in the USA. ... Lipoatrophic diabetes mellitus. D003923. EFO_0007346. -. -. 2. ... It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The ... 2 inhibitor used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It has ...
Defective crosstalk between the brain and peripheral organs contributes to the development of obesity and type 2 diabetes. Here ... Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes ... Diabetes mellitus is a metabolic disorder characterized by hyperglycemia that affects ~9% of adults worldwide.173 It results ... Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL . Leptin reverses insulin resistance and diabetes mellitus in mice ...
Familial partial lipodystrophy may also be referred to as lipoatrophic diabetes mellitus, but the essential feature is loss of ... Metabolic abnormalities include insulin-resistant diabetes mellitus with acanthosis nigricans and hypertriglyceridemia; ...
Familial partial lipodystrophy may also be referred to as lipoatrophic diabetes mellitus, but the essential feature is loss of ... Affected individuals develop insulin resistance and approximately 25%-35% develop diabetes mellitus between ages 15 and 20 ... Metabolic abnormalities include insulin-resistant diabetes mellitus with acanthosis nigricans and hypertriglyceridemia; ...
Himsworth, HP (1936) Diabetes mellitus. Its differentiation into insulin-sensitive and insulin-insensitive types. Lancet i, 127 ... Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. Journal of Clinical Investigation 105, 271-278. ... Depressive Symptoms, Insulin Resistance, and Risk of Diabetes in Women at Midlife . Diabetes Care, Vol. 27, Issue. 12, p. 2856 ... Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet i, 785-789.Google Scholar ...
Topics: diabetes mellitus, lipoatrophic , genotype , insulin lispro , metformin , phenotype Diabetes Care August 1999, Vol.22, ... Topics: autoimmunity , diabetes mellitus, type 1 , latent autoimmune diabetes of adulthood Diabetes Care August 1999, Vol.22, ... Diabetes insipidus, diabetes mellitus, optic atrophy, and deafness. A Hernandez-Mijares; C Morillas; Lluch; M L Martinez- ... Topics: creatinine clearance , diabetes mellitus, type 1 , vascular flow , vitamin e Diabetes Care August 1999, Vol.22, 1245- ...
This review summarizes the regulatory role of MG53 in cardiac tissues, current debates regarding MG53 in diabetes and diabetic ... Development of non-insulin-dependent diabetes mellitus in the double knockout mice with disruption of insulin receptor ... Lipoatrophic diabetes in Irs1(-/-)/Irs3(-/-) double knockout mice. Genes Dev. 2002;16:3213-22. ... MG53 does not manifest the development of diabetes in db/db mice. Diabetes. 2020;69:1052-64. ...
Even after being diagnosed with diabetes type 1, Frans kept being very activate and doing sports. But after talking with other ... Diabetes mellitus (incl subtypes). *Diabetes mellitus inadequate control. *Acquired lipoatrophic diabetes. *Diabetes mellitus ... Having diabetes can be quiet scary but one can always learn from your story and just like Hard carbon fiber hats. which are ... Having diabetes can be quiet scary but one can always learn from your story and just like Hard carbon fiber hats. which are ...
Representative examples include diabetes mellitus, hyperthyroidism, and adrenal gland insufficiency. ... Latent autoimmune diabetes in adults. *Leprechaunism syndrome. *Lipoatrophic diabetes. *Maturity onset diabetes mellitus in ... Diabetes insipidus*Adipsic Diabetes Insipidus. *Central diabetes insipidus*Autosomal Dominant Neurohypophyseal Diabetes ... Representative examples include diabetes mellitus, hyperthyroidism, and adrenal gland insufficiency. [from NCI] ...
Citrus sinensis , Diabetes Mellitus Tipo 2 , Resistência à Insulina , Animais , Biomarcadores , Ésteres do Colesterol , Citrus ... Noteworthy, this previously unrecognized cycle may also explain the increased energy expenditure displayed by lipoatrophic mice ... Animais , Resistência à Insulina/fisiologia , Biomarcadores , Citrus sinensis/metabolismo , Diabetes Mellitus , Triglicerídeos ... BACKGROUND & AIMS: Dyslipidaemia is usually common in obesity, insulin resistance, and type 2 diabetes mellitus. Clinical ...
Diabetes Mellitus, Lipoatrophic Diabetes Mellitus, Maturity Onset Diabetes Mellitus, Maturity-Onset Diabetes Mellitus, Non ... Diabetes Mellitus, Sudden-Onset Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Type I Diabetes Mellitus ... Diabetes Mellitus Diabetes Mellitus Complication Diabetes Mellitus Complications Diabetes Mellitus, Adult Onset Diabetes ... Diabetes Mellitus, Noninsulin Dependent Diabetes Mellitus, Slow Onset Diabetes Mellitus, Slow-Onset Diabetes Mellitus, Stable ...
Acquired lipoatrophic diabetes. *. Diabetes mellitus malnutrition-related. *. Diabetes mellitus inadequate control. *. Obesity ...
... had been diagnosed as having border line diabetes with hyperinsulinemia at age 12 when she was not obese and diabetes mellitus ... In contrast to our lipoatrophic patients treated with r-metHuLeptin, these two patients had a higher percent body fat and low- ... only the mother and one child had overt type 2 diabetes mellitus. Because of the unusual association of autoimmune thyroid ... Maternally inherited diabetes and deafness was ruled out since no mutations were found in mitochondria dna. Insulin receptor ...
Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).. ... Generalized Lipodystrophy: Practice Essentials, Pathophysiology, Lipoatrophic Diabetes (emedicine.medscape.com). Nutritional ... Generalized Lipodystrophy: Practice Essentials, Pathophysiology, Lipoatrophic Diabetes. Indirect calorimetry. Baillieres Clin ... In the medical field, insulin is used to treat diabetes and other conditions related to high blood sugar levels. It is ...
... and lipoatrophic diabetes) Arthrogryposis and ED Camarena syndrome Cleft lip/palate-ED syndrome (CLPED1; Zlotogora-Ogur ... insulin-resistant diabetes mellitus, and somatic abnormalities Rothmund-Thomson syndrome (RTS) Schinzel-Giedion midface- ...
4. Diabetes mellitus coexisted with progeria: a case report of atypical Werner syndrome with novel LMNA mutations and ... Generalized Lipodystrophy: Practice Essentials, Pathophysiology, Lipoatrophic Diabetes (emedicine.medscape.com). Dermatologic ... A cluster of metabolic risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic ... The net metabolic outcome in patients of diabetes with a syndrome or a condition (e.g., a with secondary diabetes thus depends ...
The cell size and distribution of adipocytes from subcutaneous and visceral fat is associated with type 2 diabetes mellitus in ... which were then tested for their adipogenic potential in vitro and in vivo after transplantation in lipoatrophic A-Zip mice [29 ... Obesity and its metabolic complications (e.g. type 2 diabetes, cardiometabolic disorders) contributing to the metabolic ... Increasing BAT/beige mass has been suggested as a potential therapeutic approach to treat human obesity/diabetes supported by ...
Acanthosis nigricans among women with gestational diabetes mellitus and risk of adverse pregnancy outcomes. Diabetes Care. 2008 ... The type B syndrome generally occurs in women who have uncontrolled diabetes mellitus, ovarian hyperandrogenism, or an ... the Cherokee Diabetes Study. Diabetes Care. 2002 Jun. 25(6):1009-14. [QxMD MEDLINE Link]. ... the American Diabetes Association established acanthosis nigricans as a formal risk factor for the development of diabetes in ...
The implication of TP variants in atypical forms of monogenic diabetes shows that genetic diagnosis of lipodystrophic syndromes ... Diabetes Mellitus, Lipoatrophic* Actions. * Search in PubMed * Search in MeSH * Add to Search ... TYMP homozygous pathogenic variant in a newly-characterized lipoatrophic diabetes. A Genealogical trees and… ... TYMP homozygous pathogenic variant in a newly-characterized lipoatrophic diabetes. A Genealogical trees and segregation ...
Insulin resistance and type 2 diabetes mellitus are frequent complications of obesity. Lipoatrophic (or lipodystrophic) ... Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. Oksana Gavrilova,1 Bernice Marcus-Samuels,1 ... However, the A-ZIP/F-1 mice provide a way to test rigorously the role of WAT in the etiology of lipoatrophic diabetes. If the ... In lipoatrophic diabetes, a lack of fat is associated with insulin resistance and hyperglycemia. This is in striking contrast ...
Diabetes Mellitus, Lipoatrophic/genetics*; Diabetes Mellitus, Lipoatrophic/physiopathology*; Epoxide Hydrolases/genetics*; ... We identified two de novo variants located in EPHX1 catalytic site in patients with a lipoatrophic diabetes characterized by ... Title: EPHX1 mutations cause a lipoatrophic diabetes syndrome due to impaired epoxide hydrolysis and increased cellular ...
Diabetes Mellitus, Lipoatrophic. A type of diabetes mellitus that is characterized by severe INSULIN RESISTANCE and ... Diabetes Mellitus, Type 1. A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the ... Diabetes Mellitus, Type 2. A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is ... Diabetes Mellitus, Experimental. Diabetes mellitus induced experimentally by administration of various diabetogenic agents or ...
No patients experienced diabetes mellitus (normal fasted glycemia in all study patients) or organ dysfunction (HR on physical ... diabetes mellitus, renal or hepatic failure, gastrointestinal disorders, or drug intake (biguanides, ethanol, methanol, and ...
Diabetes Mellitus;. Hypertriglyceridemia;. Lipodystrophy Recruitment Keyword(s). Lipodystrophy; Leptin; Lipoatrophic Diabetes; ... 1. Presence of diabetes as defined by the 2007 ADA criteria a. Fasting plasma glucose greater than or equal to 126 mg/dL, or b ... National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIHBC 10 - CRC BG RM 6-5942. 10 CENTER DR. BETHESDA MD ... National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIHBC 10 - CRC BG RM 5-3961. 10 CENTER DR. BETHESDA MD ...
Diabetes Mellitus [C19.246] * Diabetes Mellitus, Type 2 [C19.246.300] * Diabetes Mellitus, Lipoatrophic [C19.246.300.500] ... Diabetes Mellitus [C18.452.394.750] * Diabetes Mellitus, Type 2 [C18.452.394.750.149] * Diabetes Mellitus, Lipoatrophic [ ... Diabetes Mellitus, Lipoatrophic Preferred Concept UI. M0006154. Scope Note. A type of diabetes mellitus that is characterized ... Lipoatrophic Diabetes Previous Indexing. Diabetes Mellitus (1966-1978). Lipodystrophy (1966-1978). Public MeSH Note. 79. ...
Diabetes Mellitus [C19.246] * Diabetes Mellitus, Type 2 [C19.246.300] * Diabetes Mellitus, Lipoatrophic [C19.246.300.500] ... Diabetes Mellitus [C18.452.394.750] * Diabetes Mellitus, Type 2 [C18.452.394.750.149] * Diabetes Mellitus, Lipoatrophic [ ... Diabetes Mellitus, Lipoatrophic Preferred Concept UI. M0006154. Scope Note. A type of diabetes mellitus that is characterized ... Lipoatrophic Diabetes Previous Indexing. Diabetes Mellitus (1966-1978). Lipodystrophy (1966-1978). Public MeSH Note. 79. ...
2007; see DIABETES MELLITUS, LIPOATROPHIC 2005-2006. History Note:. 2007; use DIABETES MELLITUS, LIPOATROPHIC 2005-2006. ...
Acanthosis nigricans among women with gestational diabetes mellitus and risk of adverse pregnancy outcomes. Diabetes Care. 2008 ... The type B syndrome generally occurs in women who have uncontrolled diabetes mellitus, ovarian hyperandrogenism, or an ... the Cherokee Diabetes Study. Diabetes Care. 2002 Jun. 25(6):1009-14. [QxMD MEDLINE Link]. ... the American Diabetes Association established acanthosis nigricans as a formal risk factor for the development of diabetes in ...
Familial lipodystrophic diabetes Active Synonym false false 1495355018 Lipoatrophic diabetes mellitus Active Synonym false ...
Diabetes Mellitus Tipo 1/sangue , Diabetes Mellitus Tipo 1/complicações , Hipoglicemiantes/efeitos adversos , Insulina/efeitos ... On histopathology, scant, or no inflammatory infiltrate was found in lipoatrophic and lipohypertrophic areas, respectively. ... Lipodystrophy often leads to worsening of glycemic control in type 1 diabetes mellitus. Our objective was to identify the ... Associations of insulin-induced lipodystrophy in children, adolescents, and young adults with type 1 diabetes mellitus using ...
C13.351.968.419.135.500 Diabetes Insipidus, Neurogenic C13.351.968.419.135.750 Diabetes Mellitus, Lipoatrophic C17.800.849.391. ... D4.615.723.795.235 Diabetes Insipidus C13.351.968.419.135 Diabetes Insipidus, Nephrogenic ...
Gestational diabetes. Adapted from American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes ... Type 1 Diabetes Mellitus. Type 1 diabetes mellitus (T1DM) is the second most common chronic disease of childhood. It has two ... Type 2 Diabetes Mellitus. Although still rare in children and adolescents, type 2 diabetes mellitus (T2DM) has become more ... and neonatal diabetes), and other causes (Box 71-1). Although type 2 diabetes accounts for 90% to 95% of diabetes in the United ...
Diabetes mellitus (incl subtypes). *. Diabetes mellitus inadequate control. *. Acquired lipoatrophic diabetes. *. Diabetes ... You are looking for all the solutions related to Diabetes mellitus (incl subtypes) ... Diabetes mellitus inadequate control. *. Diabetes mellitus (incl subtypes). *. Glucose metabolism disorders (incl diabetes ... Diabetes mellitus (incl subtypes). *. Diabetes mellitus inadequate control. *. Glucose metabolism disorders (incl diabetes ...
Lipoatrophic diabetesBSCL; Berardinelli-Seip congenital lipodystrophy; Berardinelli-Seip syndrome; CGL; Lipoatrophic diabetes. ... resulting in diabetes mellitus, abnormal accumulation of fat in the liver (liver steatosis) and the accumulation of fat in the ... resulting in diabetes mellitus, abnormal accumulation of fat in the liver (liver steatosis) and the accumulation of fat in the ... resulting in diabetes mellitus, abnormal accumulation of fat in the liver (liver steatosis) and the accumulation of fat in the ...
... the evidence base to support obesity as the major driver of type 2 diabetes mellitus (T2DM), and the mechanisms by which this ... In line with this observation, rapid resolution of diabetes linked to a preferential and rapid reduction in liver fat has been ... This ectopic fat concept, in turn, broadly fits with the observation that individuals of similar ages can develop diabetes at ... are more likely to develop diabetes at a younger age and/or lower BMI than those without. Obesity is the major risk factor for ...
Diabetes Mellitus Diabetes Mellitus, Experimental Diabetes Mellitus, Lipoatrophic Diabetes Mellitus, Type 1 Diabetes Mellitus, ... Diabetes Complications Diabetes Insipidus Diabetes Insipidus, Nephrogenic Diabetes Insipidus, Neurogenic ... Type 2 Diabetes, Gestational Diabetic Angiopathies Diabetic Cardiomyopathies Diabetic Coma Diabetic Foot Diabetic Ketoacidosis ...
PMID- 14068842 TI - DIABETES MELLITUS IN HYPERPHAGIC MONKEYS. PMID- 14068843 TI - EFFECT OF OXYTOCIN ON OVULATION IN RABBITS ... PMID- 14068079 TI - LIPOATROPHIC DIABETES. ISOLATION AND CHARACTERIZATION OF AN INSULIN ANTAGONIST FROM URINE. PMID- 14068080 ... PMID- 14069133 TI - ADVANCES IN THE TREATMENT OF DIABETES MELLITUS. PMID- 14069134 TI - ADVANCES IN THE TREATMENT OF CANCER. ... PMID- 14067739 TI - DISAPPEARANCE RATE OF TOLBUTAMIDE IN NORMAL SUBJECTS AND IN DIABETES MELLITUS, LIVER CIRRHOSIS, AND RENAL ...
Acquired lipoatrophic diabetes. *. Diabetes mellitus malnutrition-related. *. Diabetes mellitus inadequate control. *. Obesity ...
Elevated First-Trimester Neutrophil Count Is Closely Associated With the Development of Maternal Gestational Diabetes Mellitus ... Transgenic mice lacking white fat: models for understanding human lipoatrophic diabetes. . Ann N Y Acad Sci ... Obesity is the single greatest predictor of the development of type 2 diabetes and has become a global pandemic with 475 ... Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the ...
Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem 274: ... lipoatrophic B6 mice have more marked steatosis and lower serum triglycerides than lipoatrophic FVB/N mice. Similarly, the ob/ ... Haffner SM: Pre-diabetes, insulin resistance, inflammation and CVD risk. Diabetes Res Clin Pract 61 (Suppl. 1):S9 -S18, 2003 35 ... Diabetes 54:1314 -1323, 2005. From the 1Research Division, Joslin Diabetes Center, and Department of Medicine, Harvard Medical ...
  • The European Association for the Study of Diabetes Annual Meeting, 1998: complications of diabetes. (diabetesjournals.org)
  • An autosomal recessive disorder that causes premature aging in adults, characterized by sclerodermal skin changes, cataracts, subcutaneous calcification, muscular atrophy, a tendency to diabetes mellitus, aged appearance of the face, baldness, and a high incidence of neoplastic disease. (lookformedical.com)
  • The Classification suggested by American Diabetes Association (ADA) is called as the etiological classification of diabetes and has the two main types of diabetes labeled as type 1 and type 2, along with gestational diabetes mellitus and the other specific types where a precise etiological factor is identified. (nurseinfo.in)
  • Diabetes mellitus (DM) is the metabolic homeostasis disorder regulated by insulin which causes abnormalities in the carbohydrate and lipid metabolism. (wikidoc.org)
  • thereby achieving the full metabolic normalization not yet possible and making some degree of hyperglycemia persists in virtually all patients with diabetes. (wikidoc.org)
  • Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia with or without glycosuria, resulting from an absolute or relative deficiency of insulin. (nurseinfo.in)
  • Insulin resistance underlies a constellation of adverse metabolic and physiological changes (the insulin resistance syndrome) which is a strong risk factor for development of type 2 diabetes and CHD. (cambridge.org)
  • Obesity and its metabolic complications (e.g. type 2 diabetes, cardiometabolic disorders) contributing to the metabolic syndrome represent one of the most important public health problems, with societal and economic implications urging for new therapeutic strategies and effective social policies. (springer.com)
  • Lipoatrophic diabetes is a type of diabetes mellitus presenting with severe lipodystrophy in addition to the traditional signs of diabetes. (wikipedia.org)
  • Von Mering and Minkowski while experimenting on dogs found that removal of the pancreas led to diabetes. (wikidoc.org)
  • The cut-off level of fasting plasma glucose (FPG) for diagnosis of diabetes has been fixed as 126 mg/dl, since this reflects the same degree of hyperglycemia as a 2hr-PG of 200 mg/dl in terms of susceptibility for the development of microvascular and macrovascular complications. (nurseinfo.in)
  • [ 2 ] However, it is known that millions of US individuals have obesity and type 2 diabetes mellitus . (medscape.com)
  • Defective crosstalk between the brain and peripheral organs contributes to the development of obesity and type 2 diabetes. (nature.com)
  • However, in the context of sustained obesity, WAT undergoes fibro-inflammation, which compromises its functionality, contributing to increased risk of type 2 diabetes and cardiovascular diseases. (springer.com)
  • In 2000, the American Diabetes Association established acanthosis nigricans as a formal risk factor for the development of diabetes in children. (medscape.com)
  • Insulin-resistance syndromes include those with mutations in the insulin receptors (ie, leprechaunism, Rabson-Mendenhall syndrome), peroxisome proliferator-activated receptor gamma (ie, type 1 diabetes with acanthosis nigricans and hypertension), 1-acylglycerol-3-phosphate O-acyl transferase-2 or seipin (Berardinelli-Seip syndrome), lamin A/C (Dunnigan syndrome), and Alstrom syndrome gene. (medscape.com)
  • Type 1 diabetes (also called juvenile-onset diabetes mellitus, DM1, T1DM, and insulin-dependent diabetes mellitus) is considered an immuno-mediated disease that results in a gradual destruction of insulin-producing pancreatic beta cells, and subsequently leads to their complete loss and total dependence on exogenous insulin. (wikidoc.org)
  • Type 2 diabetes mellitus (T2DM) is characterized by two underlying defects. (wikidoc.org)
  • The ancient Indian physician, Sushruta, and the surgeon Charaka discovered the two forms of DM which are later classified as Type I and Type 2 diabetes. (wikidoc.org)
  • Type-1 diabetes mellitus has been classified into type-1A in which cell-mediated autoimmune attack on the beta cells is more prominent and type-1B in which the mechanism is less clear. (nurseinfo.in)
  • It is used to treat type 2 diabetes mellitus in the USA. (pharmakb.com)
  • It has been approved in Europe to treat type 2 diabetes mellitus. (pharmakb.com)
  • Sustained improvement of glycemic control by insulin treatment after 9 years in patients with type 2 diabetes and secondary failure. (diabetesjournals.org)
  • This review summarizes the regulatory role of MG53 in cardiac tissues, current debates regarding MG53 in diabetes and diabetic cardiomyopathy, as well as highlights potential clinical applications of MG53 in treating cardiac pathologies. (biomedcentral.com)
  • Her mother was diabetic, and her father and sister had border line diabetes, whereas her brother had a normal response. (lookfordiagnosis.com)
  • Clinically diabetes is characterized by a wide spectrum of disorders ranging from asymptomatic hyperglycemia to abnormalities in the various organs. (nurseinfo.in)
  • We identified two de novo variants located in EPHX1 catalytic site in patients with a lipoatrophic diabetes characterized by loss of adipose tissue, insulin resistance, and multiple organ dysfunction. (nih.gov)
  • The leptin deficiency usually causes high blood lipid (fat) levels and insulin resistance that may lead to diabetes. (nih.gov)
  • EPHX1 mutations cause a lipoatrophic diabetes syndrome due to impaired epoxide hydrolysis and increased cellular senescence. (nih.gov)
  • Successful pregnancy in a woman with lipoatrophic diabetes mellitus. (wikipedia.org)
  • Diabetes mellitus induced by PREGNANCY but resolved at the end of pregnancy. (nih.gov)
  • A rare autosomal dominant genetically heterogeneous hereditary form of diabetes mellitus which is distinct from Type I diabetes mellitus and affected individuals present with insulin-requiring hyperglycemia within the first 3 months of life. (nih.gov)
  • Adapted from American Diabetes Association: Diagnosis and classification of diabetes mellitus. (clinicalgate.com)
  • In line with this observation, rapid resolution of diabetes linked to a preferential and rapid reduction in liver fat has been noted with significant caloric reduction. (biomedcentral.com)
  • This ectopic fat concept, in turn, broadly fits with the observation that individuals of similar ages can develop diabetes at markedly different body mass indexes (BMIs). (biomedcentral.com)
  • Conditions or pathological processes associated with the disease of diabetes mellitus . (nih.gov)
  • and Botero D, Wolfsdorf JI: Diabetes mellitus in children and adolescents. (clinicalgate.com)
  • Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. (nih.gov)
  • Those with diabetes measure their blood glucose levels daily before each meal and at bedtime. (nih.gov)